Progressive Corporation/ US7433151039 /
5/17/2024 5:06:51 PM | Chg. +0.66 | Volume | Bid5:07:08 PM | Ask5:07:08 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
207.67USD | +0.32% | 334,314 Turnover: 49.33 mill. |
207.67Bid Size: 100 | 207.78Ask Size: 100 | 121.57 bill.USD | 0.19% | 31.40 |
GlobeNewswire
1:00 PM
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
GlobeNewswire
5/16
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical t...
GlobeNewswire
5/16
BMW unveils The BMW XM Mystique Allure, a one-of-a-kind luxury vehicle inspired by the iconic superm...
GlobeNewswire
5/15
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III P...
GlobeNewswire
5/14
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment...
GlobeNewswire
5/13
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Ap...
GlobeNewswire
5/13
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transt...
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/9
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st ...
GlobeNewswire
5/9
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate...
GlobeNewswire
5/8
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Plan...
GlobeNewswire
5/7
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...
GlobeNewswire
5/6
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire
5/4
The National Fire Sprinkler Association's Class of 2024: Honoring Fire Sprinkler Industry Greats
GlobeNewswire
5/2
PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Targ...
GlobeNewswire
5/1
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...
GlobeNewswire
5/1
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 ...
GlobeNewswire
5/1
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evalu...